42 filings
8-K
INAB
IN8bio Inc
9 May 24
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
4:04pm
8-K
INAB
IN8bio Inc
14 Mar 24
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
4:09pm
8-K
INAB
IN8bio Inc
11 Dec 23
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
5:15pm
8-K
INAB
IN8bio Inc
11 Dec 23
Other Events
8:56am
8-K
INAB
IN8bio Inc
7 Dec 23
Departure of Directors or Certain Officers
4:15pm
8-K
yxmtek7 yf
20 Nov 23
Other Events
9:04am
8-K
qsgjpt0 ya
9 Nov 23
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
0b1jvi mopcu652pr5
12 Oct 23
Other Events
8:09am
8-K
bewz5
10 Aug 23
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
5:28pm
8-K
8n5wl
16 Jun 23
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
gm4j6j0a6udsrn0f
5 Jun 23
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
8:12am
8-K
33ffp
17 May 23
Other Events
8:10am
8-K
ocwv0x9pbr308 9y
12 May 23
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
8:02am
8-K
tykratbd2yp6j50f6cc
1 May 23
Departure of Directors or Certain Officers
4:13pm
8-K
lvb4l ub7
24 Apr 23
Regulation FD Disclosure
8:19am
8-K
ix4 0rknt7ssykf4qh
17 Apr 23
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
4:02pm
8-K
juk4m9
30 Mar 23
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
4:20pm
8-K
sg8yaiuklnquvb
10 Mar 23
Regulation FD Disclosure
9:03pm
8-K
4xj43bibznpfhuu
23 Feb 23
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
7:08am
8-K
2k8c7afz
5 Jan 23
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
7:08am